Project Grant R01CA292664
Award Date
8/13/24
Completion Date
7/31/29
Dollars Obligated
$1.3M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The National Cancer Institute (NCI), through the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $1,220,394 project grant to the Sloan-Kettering Institute for Cancer Research in New York. The 5-year grant, awarded on September 15, 2024, will fund research to comprehensively characterize the acute and chronic neurotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. The research aims to investigate the molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $176,040 to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027. The project aims to develop new strategies to engineer CAR-T cell therapies that can overcome the cancer cell glycocalyx barrier for improved immunotherapy, particularly for solid tumors like breast cancer and glioblastoma. Key objectives include...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program 93.395 Cancer Treatment Research (CFDA 93.395), is funding the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The $402,600 award, granted on Apr 3, 2025, supports research by the Sloan-Kettering Institute for Cancer Research to: (1) test the efficacy and...
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $627,272 project grant to The Johns Hopkins University on Feb 24, 2025 to develop and optimize engineered, self-propelled tumor-infiltrating CAR T cells using synthetic cytokine receptors (velocity receptors) to enhance their migration speed and tumor infiltration capabilities. The goal is to improve the efficacy of CAR T cell therapy for treating pancreatic cancer, which has a 5-year survival rate of just ~12%....
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $452,540 to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will enable real-time monitoring of endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma undergoing bispecific T-cell engager antibody (BiTEA) treatments. The goal is to better understand mechanisms of therapy...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
The National Cancer Institute (NCI) awarded a $798,512 Project Grant under CFDA 93.395 - Cancer Treatment Research to Luminary Therapeutics, Inc., a small disadvantaged business, to develop an allogeneic gamma/delta armored dual-targeting chimeric antigen receptor (CAR) T-cell therapy to treat epithelial ovarian carcinoma. The project aims to address key challenges with CAR T-cell therapies against solid tumors, including antigen escape and the immunosuppressive tumor microenvironment, through...